Literature DB >> 24096630

HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathways.

Rachel P Simmons1, Eileen P Scully, Erin E Groden, Kelly B Arnold, J Judy Chang, Kim Lane, Jeff Lifson, Eric Rosenberg, Douglas A Lauffenburger, Marcus Altfeld.   

Abstract

OBJECTIVE: To study the cytokine/chemokine profiles in response to HIV-1 viremia, and elucidate the pathways leading to HIV-1-induced inflammation. DESIGN/
METHODS: Plasma levels of 19 cytokines in individuals with early HIV-1 infection and individuals undergoing treatment interruptions were evaluated via multiplex assay. To investigate the cellular sources of relevant cytokines, sorted cells from HIV-1 infected individuals were assessed for mRNA expression. Relevant signaling pathways were assessed by comparing cytokine production patterns of peripheral blood mononuclear cells stimulated with intact HIV-1 or specific Toll-like receptor (TLR) stimulants with and without a TLR7/9 antagonist.
RESULTS: IP-10 plasma concentration was most significantly associated with HIV-1 viral load and was the most significant contributor in a multivariate model. IP-10 mRNA was highly expressed in monocytes and mDCs and these cells were the dominant producers after in-vitro stimulation with TLR7/8 ligands (CL097 and ssRNAGag1166), AT-2 HIV-1, and HIV-1NL43 virus. Partial least square discriminant analysis of culture supernatants revealed distinct cytokine/chemokine secretion profiles associated with intact viruses compared with TLR7/8 ligands alone, with IP-10 production linked to the former. A TLR7/9 antagonist blocked IP-10 production following whole virus stimulation, suggesting the involvement of TLR7/9 in the recognition of HIV-1 by these cells.
CONCLUSION: Monocytes and mDCs produce significant amounts of IP-10 in response to HIV-1 viremia and after in-vitro stimulation with HIV-1. Stimulation with HIV-1-derived TLR7/8-ligands versus HIV-1 resulted in distinct cytokine/chemokine profiles, indicating additional pathways other than TLR7/8 that lead to the activation of innate immune cells by HIV-1.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24096630      PMCID: PMC4288813          DOI: 10.1097/01.aids.0000432455.06476.bc

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  46 in total

1.  Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras.

Authors:  Nancy F Crum; Robert H Riffenburgh; Scott Wegner; Brian K Agan; Sybil A Tasker; Katherine M Spooner; Adam W Armstrong; Susan Fraser; Mark R Wallace
Journal:  J Acquir Immune Defic Syndr       Date:  2006-02-01       Impact factor: 3.731

2.  Roles for CXC chemokine ligands 10 and 11 in recruiting CD4+ T cells to HIV-1-infected monocyte-derived macrophages, dendritic cells, and lymph nodes.

Authors:  John F Foley; Cheng-Rong Yu; Rikki Solow; Maureen Yacobucci; Keith W C Peden; Joshua M Farber
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

3.  Survival of persons with and without HIV infection in Denmark, 1995-2005.

Authors:  Nicolai Lohse; Ann-Brit Eg Hansen; Gitte Pedersen; Gitte Kronborg; Jan Gerstoft; Henrik Toft Sørensen; Michael Vaeth; Niels Obel
Journal:  Ann Intern Med       Date:  2007-01-16       Impact factor: 25.391

4.  Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Authors:  Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

5.  Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.

Authors:  Z Liu; W G Cumberland; L E Hultin; H E Prince; R Detels; J V Giorgi
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-10-01

6.  Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study.

Authors:  J V Giorgi; Z Liu; L E Hultin; W G Cumberland; K Hennessey; R Detels
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-08

7.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

Authors:  Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Barry Bredt; Elilta Hagos; Harry Lampiris; Steven G Deeks
Journal:  J Infect Dis       Date:  2003-04-23       Impact factor: 5.226

8.  Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

Authors:  Peter W Hunt; Steven G Deeks; Benigno Rodriguez; Hernan Valdez; Starley B Shade; Donald I Abrams; Mari M Kitahata; Melissa Krone; Torsten B Neilands; Richard J Brand; Michael M Lederman; Jeffrey N Martin
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

9.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

10.  Limited durability of viral control following treated acute HIV infection.

Authors:  Daniel E Kaufmann; Mathias Lichterfeld; Marcus Altfeld; Marylyn M Addo; Mary N Johnston; Paul K Lee; Bradford S Wagner; Elizabeth T Kalife; Daryld Strick; Eric S Rosenberg; Bruce D Walker
Journal:  PLoS Med       Date:  2004-10-26       Impact factor: 11.069

View more
  44 in total

Review 1.  Friend or Foe: Innate Sensing of HIV in the Female Reproductive Tract.

Authors:  Nadia R Roan; Martin R Jakobsen
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

2.  TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women.

Authors:  Pascal Azar; José Enrique Mejía; Claire Cenac; Arnoo Shaiykova; Ali Youness; Sophie Laffont; Asma Essat; Jacques Izopet; Caroline Passaes; Michaela Müller-Trutwin; Pierre Delobel; Laurence Meyer; Jean-Charles Guéry
Journal:  JCI Insight       Date:  2020-06-18

3.  HIV-1 single-stranded RNA induces CXCL13 secretion in human monocytes via TLR7 activation and plasmacytoid dendritic cell-derived type I IFN.

Authors:  Kristen W Cohen; Anne-Sophie Dugast; Galit Alter; M Juliana McElrath; Leonidas Stamatatos
Journal:  J Immunol       Date:  2015-02-09       Impact factor: 5.422

4.  Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV.

Authors:  Anne-Sophie Dugast; Kelly Arnold; Giuseppe Lofano; Sarah Moore; Michelle Hoffner; Melissa Simek; Pascal Poignard; Michael Seaman; Todd J Suscovich; Florencia Pereyra; Bruce D Walker; Doug Lauffenburger; Douglas S Kwon; Brandon F Keele; Galit Alter
Journal:  Clin Infect Dis       Date:  2017-04-15       Impact factor: 9.079

5.  Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression.

Authors:  Daniel T Claiborne; Jessica L Prince; Eileen Scully; Gladys Macharia; Luca Micci; Benton Lawson; Jakub Kopycinski; Martin J Deymier; Thomas H Vanderford; Krystelle Nganou-Makamdop; Zachary Ende; Kelsie Brooks; Jianming Tang; Tianwei Yu; Shabir Lakhi; William Kilembe; Guido Silvestri; Daniel Douek; Paul A Goepfert; Matthew A Price; Susan A Allen; Mirko Paiardini; Marcus Altfeld; Jill Gilmour; Eric Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-17       Impact factor: 11.205

6.  SLAMF7 Is a Critical Negative Regulator of IFN-α-Mediated CXCL10 Production in Chronic HIV Infection.

Authors:  Patrick O'Connell; Yuliya Pepelyayeva; Maja K Blake; Sean Hyslop; Robert B Crawford; Michael D Rizzo; Cristiane Pereira-Hicks; Sarah Godbehere; Linda Dale; Peter Gulick; Norbert E Kaminski; Andrea Amalfitano; Yasser A Aldhamen
Journal:  J Immunol       Date:  2018-12-10       Impact factor: 5.422

7.  Systemic cytokine levels show limited correlation with risk of HIV-1 acquisition.

Authors:  Dara A Lehman; Keshet Ronen; Catherine A Blish; Jared M Baeten; Zahra Jalalian-Lechak; Walter Jaoko; Kishorchandra Mandaliya; Barbra A Richardson; R Scott McClelland; Julie Overbaugh
Journal:  J Acquir Immune Defic Syndr       Date:  2014-06-01       Impact factor: 3.731

Review 8.  HIV infection: focus on the innate immune cells.

Authors:  Milena S Espíndola; Luana S Soares; Leonardo J Galvão-Lima; Fabiana A Zambuzi; Maira C Cacemiro; Verônica S Brauer; Fabiani G Frantz
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

9.  Similar Immunological Profiles Between African Endemic and Human Immunodeficiency Virus Type 1-Associated Epidemic Kaposi Sarcoma (KS) Patients Reveal the Primary Role of KS-Associated Herpesvirus in KS Pathogenesis.

Authors:  Salum J Lidenge; For Yue Tso; Owen Ngalamika; John R Ngowi; Yasaman Mortazavi; Eun Hee Kwon; Danielle M Shea; Veenu Minhas; Julius Mwaiselage; Charles Wood; John T West
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

10.  A compartmentalized type I interferon response in the gut during chronic HIV-1 infection is associated with immunopathogenesis.

Authors:  Stephanie M Dillon; Kejun Guo; Gregory L Austin; Sara Gianella; Phillip A Engen; Ece A Mutlu; John Losurdo; Garth Swanson; Prachi Chakradeo; Ali Keshavarzian; Alan L Landay; Mario L Santiago; Cara C Wilson
Journal:  AIDS       Date:  2018-07-31       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.